NCT06924385View on ClinicalTrials.gov

Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 6, 2025

Primary Completion Date

August 31, 2025

Study Completion Date

December 31, 2025

Conditions
Preeclampsia
Interventions
DRUG

Telpegfilgrastim Injection

Telpegfilgrastim will be administered as subcutaneous (SC) injection.

DRUG

Telpegfilgrastim Injection

Telpegfilgrastim will be administered as subcutaneous (SC) injection.

DRUG

Telpegfilgrastim Injection

Telpegfilgrastim will be administered as subcutaneous (SC) injection.

DRUG

Telpegfilgrastim Injection

Telpegfilgrastim will be administered as subcutaneous (SC) injection.

DRUG

Telpegfilgrastim Injection

Telpegfilgrastim will be administered as subcutaneous (SC) injection.

Trial Locations (1)

100191

RECRUITING

Peking University Third Hospital, Beijin

All Listed Sponsors
collaborator

Peking University Third Hospital

OTHER

lead

Xiamen Amoytop Biotech Co., Ltd.

INDUSTRY